









市場行情
/
股票
/
nasdaq-prta
/

Prothena Corporation PLC

PRTA

9.540USD

-0.150-1.55%

收盤 12/26, 16:00（美東）報價延遲15分鐘

513.54M總市值

虧損本益比TTM



Prothena Corporation PLC

9.540

-0.150-1.55%

概覽公司財務分析

概覽

公司

財務

分析

關於 Prothena Corporation PLC 公司

Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

Prothena Corporation PLC簡介



公司代碼PRTA

公司名稱Prothena Corporation PLC

上市日期Dec 21, 2012

CEOKinney (Gene G)

員工數量163

證券類型Ordinary Share

年結日Dec 21

公司地址77 Sir John Rogerson's Quay, Block C

城市DUBLIN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Ireland

郵編D02 VK60

電話35312362500

網址https://www.prothena.com/

公司代碼PRTA

上市日期Dec 21, 2012

CEOKinney (Gene G)

Prothena Corporation PLC公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Brandon S. Smith

Chief Operating Officer

130.00K

Dr. Wagner M. Zago, Ph.D.

Chief Scientific Officer

85.00K

Dr. Dennis J. Selkoe, M.D.

Independent Director

4.21K

Mr. Richard T. Collier

Independent Director

1.22K

Dr. Lars G. Ekman, M.D., Ph.D.

Chairman Emeritus

243.00

Mr. Daniel G. Welch

Independent Chairman of the Board

Mr. Shane M. Cooke

Independent Director

Ms. Karin L. Walker, CPA

Chief Accounting Officer

Ms. Paula K. Cobb

Independent Director

Ms. Helen S. Kim

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Brandon S. Smith

Chief Operating Officer

130.00K

Dr. Wagner M. Zago, Ph.D.

Chief Scientific Officer

85.00K

Dr. Dennis J. Selkoe, M.D.

Independent Director

4.21K

Mr. Richard T. Collier

Independent Director

1.22K

Dr. Lars G. Ekman, M.D., Ph.D.

Chairman Emeritus

243.00

Mr. Daniel G. Welch

Independent Chairman of the Board

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

Fidelity Management & Research Company LLC

14.68%

Scully (William P)

9.81%

Fennell (Todd W.)

8.35%

BlackRock Institutional Trust Company, N.A.

5.51%

The Vanguard Group, Inc.

3.81%

其他

57.84%

持股股東

佔比

Fidelity Management & Research Company LLC

14.68%

Scully (William P)

9.81%

Fennell (Todd W.)

8.35%

BlackRock Institutional Trust Company, N.A.

5.51%

The Vanguard Group, Inc.

3.81%

其他

57.84%

股東類型

持股股東

佔比

Investment Advisor

35.22%

Hedge Fund

23.86%

Individual Investor

19.39%

Investment Advisor/Hedge Fund

15.99%

Research Firm

4.34%

Pension Fund

0.19%

Bank and Trust

0.16%

Sovereign Wealth Fund

0.11%

Venture Capital

0.03%

其他

0.71%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

450

41.85M

77.74%

-15.20M

2025Q2

460

51.33M

95.35%

-19.91M

2025Q1

472

64.29M

119.45%

-7.39M

2024Q4

479

65.24M

121.19%

+239.99K

2024Q3

476

59.39M

110.43%

-5.39M

2024Q2

479

58.48M

108.76%

-4.67M

2024Q1

472

60.86M

113.29%

-264.94K

2023Q4

474

56.64M

105.77%

-2.21M

2023Q3

476

55.90M

104.65%

-1.73M

2023Q2

475

55.02M

104.46%

-3.12M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Fidelity Management & Research Company LLC

7.90M

14.68%

-40.18K

-0.51%

Jun 30, 2025

Scully (William P)

5.35M

9.94%

-255.90K

-4.56%

Jun 30, 2025

Fennell (Todd W.)

4.35M

8.08%

-239.96K

-5.23%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.12M

5.8%

-162.75K

-4.95%

Jun 30, 2025

The Vanguard Group, Inc.

2.17M

4.03%

+906.96K

+71.95%

Jun 30, 2025

Armistice Capital LLC

2.24M

4.15%

+40.00K

+1.82%

Jun 30, 2025

Adar1 Capital Management LLC

3.38M

6.27%

+3.38M

Jun 30, 2025

Palo Alto Investors LP

1.27M

2.37%

-384.98K

-23.20%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Virtus LifeSci Biotech Clinical Trials ETF

1.44%

iShares Neuroscience and Healthcare ETF

0.78%

Invesco NASDAQ Future Gen 200 ETF

0.7%

Federated Hermes MDT Small Cap Core ETF

0.62%

ALPS Medical Breakthroughs ETF

0.24%

ProShares Ultra Nasdaq Biotechnology

0.07%

Invesco Nasdaq Biotechnology ETF

0.06%

Avantis US Small Cap Equity ETF

0.04%

iShares Biotechnology ETF

0.04%

WisdomTree US SmallCap Fund

0.03%

Virtus LifeSci Biotech Clinical Trials ETF

佔比1.44%

iShares Neuroscience and Healthcare ETF

佔比0.78%

Invesco NASDAQ Future Gen 200 ETF

佔比0.7%

Federated Hermes MDT Small Cap Core ETF

佔比0.62%

ALPS Medical Breakthroughs ETF

佔比0.24%

ProShares Ultra Nasdaq Biotechnology

佔比0.07%

Invesco Nasdaq Biotechnology ETF

佔比0.06%

Avantis US Small Cap Equity ETF

佔比0.04%

iShares Biotechnology ETF

佔比0.04%

WisdomTree US SmallCap Fund

佔比0.03%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Prothena Corporation PLC的前五大股東是誰？



Prothena Corporation PLC的前五大股東如下：
Fidelity Management & Research Company LLC
持有股份：7.90M
佔總股份比例：14.68%。
Scully (William P)
持有股份：5.35M
佔總股份比例：9.94%。
Fennell (Todd W.)
持有股份：4.35M
佔總股份比例：8.08%。
BlackRock Institutional Trust Company, N.A.
持有股份：3.12M
佔總股份比例：5.80%。
The Vanguard Group, Inc.
持有股份：2.17M
佔總股份比例：4.03%。